Floatz logo

Metformin

Hyperandrogenemia

University of VirginiaSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hyperandrogenemia cohort.

Asset / SponsorPhaseRating
Letrozole
University of Virginia
Early Phase 1C
Prometrium
University of Virginia
N/AD
Spironolactone
University of Virginia
N/AD

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →